NOXXON Pharma AG announces management changes
CEO Dr Frank Morich will leave the company
Iain Buchanan, who worked with the Board of Directors since 2007 and later became a Director of NOXXON Pharma AG, will assume the role of Interim CEO with effect from September 1, 2010, and will support the board during its search for a permanent replacement.
Iain has a track record and brings to NOXXON over 30 years of experience in the pharmaceutical and biotech industry. He comes to NOXXON from Novexel in Paris where, earlier this year, he was responsible for the sale of the company to Astra Zeneca. Prior to his role as CEO of Novexel Iain has held a range of management and business development positions within a number of companies in the pharmaceutical industry including Vertex, Johnson and Johnson, Biogen, and Merck & Co.
Most read news
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.